Embodiments of the invention are directed to the administration of bryostatin and bryostatin and retinoids for the treatment of diseases that cause increased alpha secretase activity. The invention of this application includes neurodegenerative diseases such as Hutchinson's disease, Parkinson's disease, Down's syndrome, and Alzheimer's disease, and viral latent infection diseases such as HIV and herpes, cancers such as prostate cancer, melanoma, lymphoma, and kidney cancer, Targeting the treatment of ophthalmic diseases such as esophageal diseases and glaucoma.本発明の実施形態は、αセクレターゼ活性の上昇の原因となる疾患の治療のためのブリオスタチンおよびブリオスタチンおよびレチノイドの投与を対象とする。本出願の発明は、ハッチンソン病、パーキンソン病、ダウン症候群、およびアルツハイマー病等の神経変性疾患、ならびにＨＩＶおよびヘルペス等のウイルス潜伏感染疾患、前立腺癌、黒色腫、リンパ腫、および腎臓癌等の癌、食道疾患および緑内障等の眼疾患の治療を対象とする。
